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Abstract
BACKGROUND: The prevalence of metabolic syndrome (MS) in children and adolescents has increased, along with 
increasing incidence of obesity.
AIM: The aim of this study was to find out the polymorphism characteristic of cholesteryl ester transfer protein 
(CETP) -629C/A gene promoter and to prove that the CETP -629C/A polymorphism, serum CETP, and chemerin 
levels were risk factors of MS in obese adolescents.
MATERIALS AND METHODS: A matched case–control study with obese adolescent aged 11–18 years was 
conducted from May to December 2017. Samples were consecutively recruited in seven junior and senior high 
schools in Denpasar. Case groups were obese adolescents with MS and control groups were obese adolescents 
without MS (non-MS obese). Both groups fulfilled eligibility criteria were matched by gender and puberty status. The 
study data were analyzed by Chi-square test and logistic regression with significant level p < 0.05.
RESULTS: Analysis of CETP -629C/A polymorphism showed, AA and CA genotype were not a risk factors for MS 
when compared with CC genotype (OR = 0.81 [95% CI 0.23–2.88], p = 0.75 and OR = 0.95 [95% CI 0.38–2.37] 
p = 0.91, respectively). There was no significant difference between individual carriers A allele with individual carriers 
C allele to risk of MS (OR = 0.91 [95% CI 0.39–2.14], p = 0.83). The cutoff point of CETP levels was ≥2 µg/mL 
considered as CETP high levels, and <2 µg/mL considered normal; chemerin levels ≥170 ηg/mL considered as 
chemerin high levels, and <170 ηg/mL considered as normal. High levels of serum CETP were a risk factor in MS 
compared to normal levels (OR = 2.82 [95% CI 1.07–7.41], p = 0.036) and high levels of serum chemerin were a risk 
factor in MS compared to normal level (OR = 2.77 [95% CI 1.04–7.40], p = 0.042).
CONCLUSION: This study concluded that high levels of serum CETP and chemerin were the risk factors for MS, 
while genotype AA CETP -629C/A gene polymorphism was not a risk factor for MS.
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Introduction
The World Health Organization states that 
overweight and obesity in children and adolescents are 
public health problems throughout the world. Obesity is 
strongly associated with insulin resistance (IR) and is 
the underlying factor in the occurrence of the metabolic 
syndrome (MS). Thus, MS is a group of risk factors 
associated with IR that the highest prevalence found 
in obese individuals. Hence, the prevalence of MS in 
children and adolescents has increased, along with 
increasing incidence of obesity.
The prevalence of obesity in children and 
adolescents is increasing rapidly throughout the 
world. According to the National Health and Nutrition 
Examination Survey, in 2011–2012, 16.9% of children 
aged 2–19 years, and 34.9% of adults aged 20 years or 
over were obese [1], but the overall prevalence of obesity 
among children and adolescents remained unchanged 
compared to 2009–2010 (16.9%) and there were no 
significant changes from 2003 to 2004 [2]. According 
to the Riset Kesehatan Dasar (Riskesdas) 2013 
Ministry of Health’s, it showed that national overweight 
and obesity problems in children aged 5–12 years 
amounted to 10.8% and 8.8%, respectively, already 
close to the estimated world numbers in 2020 (9.1%). 
In adolescents aged 13–15 years, the prevalence 
of obesity is 10.8% with 8.3% obese and 2.5% very 
obese [3]. The prevalence of obesity at Denpasar in 
2002 was 11% in adolescents 11–17 years [4], while 
in Bali, Dewi and Sidiartha found the prevalence of 
obesity was 15% in children aged 10–12 years [5].
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MS is a cluster of the following risk factors: 
Abdominal obesity, hypertension, hypertriglyceridemia, 
fasting plasma glucose levels, and low level of 
high-density lipoprotein cholesterol (HDL-C) [6]. 
This combination is considered as a precursor to 
cardiovascular disease and type 2 diabetes mellitus 
(type 2 DM). Several studies on the prevalence of MS 
in overweight and obese children have been carried 
out in Indonesia. Research in Jakarta found that the 
prevalence of MS was 34% in 50 obese teenagers 
aged 10–19 years [7], [8]. Dwipayana et al. got that the 
prevalence of adult age in Bali at MS was 18.2% (male, 
16.6%; female, 20.0%) [8].
Some single-nucleotide polymorphisms 
(SNPs) are significantly associated with overall 
components of MS including, TCF7l2, LPL, APOA5, 
cholesteryl ester transfer protein (CETP), and 
APOC1/APOE/TOMM40 [9]. CETP is a glycoprotein 
that containing 476 amino acids with a molecular 
weight of 74 kDa has an important role in plasma 
lipoprotein remodeling [10]. CETP facilitates the 
absorption of cholesterol from peripheral tissue to 
the liver in a process known as reverse cholesterol 
transport [11]. At the same time, CETP transfers 
cholesterol esters from HDL to low-density lipoprotein 
(LDL) and very low-density lipoprotein (VLDL) 
together with triglyceride (TG) exchanges. Therefore, 
CETP can increase the atherogenicity of apoB-
containing lipoproteins and negatively affect the HDL 
levels [12], [13].
Chemerin is one of the new adipokines reported 
in 2003, which is a chemoattractant that plays role in 
the inflammatory process [14]. Chemerin is secreted 
by adipose tissue in an inactive form as prochemerin, 
then activated by proteolytic protease enzymes which 
then work on G protein-coupled receptors CMKLR1 
(chemokine receptor-like 1) on macrophages and 
dendritic cells [15]. Chemerin has an important role in 
the pathophysiology of obesity and BC [16], [17].
Materials and Methods
This study was a matched-pair case control 
and conducted on adolescent in junior and senior 
high school, Denpasar, Prodia® Laboratory, Clinical 
Pathology Laboratory, Medical Faculty, Udayana 
University/Sanglah Hospital, Unit Laboratorium 
Biomedik Terpadu, Medical Faculty, Unud, and Genetic 
Science Laboratory, Jakarta, after approved by 
Research Ethics Committee Medical Faculty, Udayana 
University/Sanglah Hospital, Denpasar. Research time 
was from May 2017 to December 2017.
The target population in our study were 
people ages 11–18 years with obesity in Bali, while 
the accessible population are obese adolescents in 
selected junior and high school ages 11–18 years 
in the city of Denpasar during the study period. The 
sample was part of an accessible population that 
met the inclusion and exclusion criteria (Figure 1). 
The sample for the case is adolescents obese with 
metabolic syndrome (MS obese) and the sample 
for control is obese adolescents without metabolic 
syndrome (non-MS obese). The selection of samples 
in our study was consecutive sampling technique, 
where all existing samples and fulfilling the research 
criteria were included in the study until the required 
number of sample was fulfilled. Sample size was 
calculated based on α = 0.05 and (β) = 10%. Based 
on the results, final sample size was 35 sample for 
each group.
Statistical analysis
Case (MS obese) and control (non MS obese)
Completion of study approval form, history taking, physical examination, body 
weight, body height, waist circumference and laboratory: TG, HDL, LDL, total 
cholesterol and fasting glucose.
Study samples
Inclusion criteria:
Obese
Ages 11- 18 years
Registered in junior and 
senior high school, Denpasar
Parents/subjects willing to 
take part in the study
Exclusion criteria:
Suffering from 
infections, autoimmune 
diseases, chronic 
diseases, malignancies.
Adolescents obese aged 11 to 18 years
DNA, CETP and serum 
chemerin examination
Figure 1: Study algorithm
The difference in output between the subject 
characteristic variables and genotype variant CETP 
-629C/A polymorphism (AA, CA, and CC genotype) is 
tested by ANOVA or Kruskal–Wallis if it did not meet 
the normality. The differences in genotype of CC, CA, 
and AA in CETP −629C/A polymorphisms and the 
differences in frequency of A and C alleles to MS risk, 
the relationship between plasma CETP/chemerin levels 
with MS risk, are tested by the Chi-squared test. The 
CETP and chemerin levels must a nominal dichotomy, 
so the cutoff point is determined by a diagnostic test. 
Confounding variables were controlled by multivariate 
logistic regression analysis. The variable included in 
the multivariate analysis was type 2 DM family history. 
The final result of logistic regression is OR (CI [95% 
confidence interval]). p < 0.05 was used as the limit of 
significance.
This study was approved by Research Ethics 
Committee Medical Faculty, Udayana University/
Sanglah Hospital, Denpasar.
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Results
There were 542 students attended to the 
counseling of the children and adolescents about obesity 
and metabolic syndrome. To students who appear clinically 
obese, was advised to take part in the study and given 
informed consent sheet, then submitted to each parents 
for participation approval. A total of 147 students were 
performed physical and laboratory tests to get subjects 
that met the inclusion criteria. Case group was 43 subjects 
obese adolescents with MS and control group was obese 
43 subjects adolescents without MS (Table 1).
In both groups, there were more boys than 
girls (boys 25 subjects and girls 18 subjects). Three 
adolescents in each group have not reached puberty yet. 
There were statistically significant differences in some 
characteristic variables between the two groups, including 
TG and HDL-C levels in cases (MS obese) and controls 
(non-MS obese) (p < 0.001). Significant differences 
were also found in family history of type 2 DM between 
MS obese and non-MS obese groups (p = 0.034), then 
bivariate and multivariate analysis were carried out.
The relationship of the subject characteristics 
between both groups and AA, CA, and CC genotypes from 
CETP -629C/A gene promoter polymorphism is shown in 
Table 2. There were no significant differences between AA, 
CA, and CC genotype in all subject characteristics variables 
such as body mass index (BMI), waist circumference (WC), 
HDL-C, TG, BW, BH, systolic and diastolic blood pressure, 
fasting blood sugar, and serum CETP levels.
Based on genotype frequencies, CETP gene in 
promoter region −629C/A, it was found that CETP -629 
AA gene genotype was less in the MS obese group than 
non-MS obese (six subjects in the MS obese group and 
seven subjects in the non-MS obese group). Bivariate 
analysis found that AA genotypes and CA genotypes were 
not MS risk factors when compared to CC genotypes 
(OR = 0.81 [95% CI 0.23–2.88], p = 0.75 and OR = 0.95, 
respectively [95% CI 0.38–2.37] p = 0.91) (Tables 3-4).
Based on allele frequency, there was no 
significant difference between individual carriers A allele 
in MS obese groups and non-MS obese with individual 
carriers C allele to risk of MS (OR = 0.91 [95% CI 0.39–
2.14], p = 0.83) (Table 3).
The researcher determined cutoff point value 
by dividing CETP levels into high and normal levels by 
considering optimal sensitivity and specificity. CETP 
levels of ≥2 µg/mL considered as high and <2 µg/mL 
considered as normal, with a sensitivity value of 72.1% 
and specificity of 60.5% (Figure 2). The value of area 
under curve (AUC) was 0.697 (69.7%) (weak). Cutoff 
point of the chemerin ≥170 ηg/mL considered as high 
level and <170 ηg/mL considered as normal, with a 
sensitivity 74.4% and a specificity 58.1% (Figure). The 
value of AUC was 0.704 (70.4%) (moderate).
Based on CETP levels, it was found that 
subjects with high levels of CETP were more in MS 
obese group compared to non-MS obese group (31 
MS obese subjects and 17 non-MS obese subjects). 
Bivariate analysis with the Chi-squared test found that 
high levels of CETP were MS risk factors (OR = 3.95 
[95% CI 1.60–9.76], p = 0.0002) (Table 4).
Based on the chemerin level, it was found that 
the subjects with high levels of chemerin were more in 
MS obese group compared than non-MS obese group. 
Bivariate analysis with the Chi-square test showed risk 
Table 2: Relationship between subject characteristics and genotype variant of polymorphism CETP −629C/A
Value AA Mean±SD or median (min-max) CA Mean±SD or median (min-max) CC Mean±SD or Median (min-max) p
IMT (kg/m2) 31.75 ± 2.2 33.28 ± 2.05 33.26 ± 2.8 0.126a
WC (cm) 96 ± 8.5 96.1 ± 6.2 98.4 ± 8.5 0.38a
HDL (mg/dL) 51 ± 7.7 48.31 ± 10.78 44.37 ± 9.5 0.052a
TG (mg/dL) 110 (61–201) 107 (45–328) 108 (37–228) 0.94b
BW (kg) 85 (73–96) 84.5 (60–101) 89 (62–108) 0.36b
BH (cm) 166 (150–173) 159.5 (145–175) 162 (150–174) 0.06b
Systolic BP (mmHg) 100 (100–120) 110 (100–130) 110 (100–130) 0.22b
Diastolic BP (mmHg) 70 (70–80) 70 (70–95) 70 (70–90) 0.52b
Fasting BG (mg/dL) 91 (77–108) 91 (71–191) 90 (74–134) 0.94b
CETP (µg/mL) 2.02 (1.2–3) 2 (1–4.6) 2.1 (1.3–7.6) 0.43b
aANOVA test, bKruskal–Wallis test. WC: Waist circumference, HDL: High-density lipoprotein, TG: Triglyceride, BW: Body weight, BH: Body height.
Table 1: Subject characteristics
Variable MS obese (n = 43) Mean ± SD or Median (min-max) Non-MS obese (n = 43) Mean ± SD or Median (min-max) p
Age (year) 16 (12–18) 16 (12–17) 0.951c
Gender (boy/girl) 25/18 25/18 1.000a
BW (kg) 88 (62–108) 85 (60–103) 0.231c
BH (cm) 164 (147–175) 161 (145–173) 0.111c
BMI (kg/m2) 32.99 (24.84–38.1) 33.09 (28.54–38.48) 0.678c
C (cm) 97.56 (±7.69) 96.64 (±7.59) 0.581b
LBW history, n (%) 2 (4.7) 5 (13.15) 0.237a
Type 2 DM history in family n (%) 13 (30.2) 5 (11.6) 0.034a
Puberty state n (%) 40 (93) 40 (93) 1.000a
Systolic BP (mmHg) 110 (100–130) 110 (100–130) 0.052c
Diastolic BP (mmHg) 70 (70–95) 70 (70–80) 0.170c
Fasting glucose (mg/dL) 91 (75–191) 89 (71–102) 0.452c
TG (mg/dL) 156 (95–328) 84 (37–122) <0.001c
HDL-C (mg/dL) 41.33 (±8.56) 52.42 (±8.34) <0.001b
CETP (µg/mL) 2.30 (1.27 –7.6) 1.86 (1–6.87) 0.002c
Chemerin (ηg/L) 215.20 (100.77–805.44) 167.82 (80.73–724.08) 0.002c
aChi-square test, bindependent t-test, cMann–Whitney U-test. BMI: Body mass index, TG: Triglyceride, CETP: Cholesteryl ester transfer protein, DM: Diabetes mellitus, HDL-C: High-density lipoprotein cholesterol, BW: Body 
weight, BH: Body height.
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Two risk factors MS as already mentioned in the 
previous studies such as gender and puberty status [19] 
and in our study matched have been performed. In our 
study, MS was more commonly found in adolescent 
boys (25 vs. 18). Other studies in the adult population 
have a higher prevalence of MS in women than in men, 
29% and 23%, respectively [20].
Table 5: Metabolic syndrome risk based on chemerin serum 
level
Chemerin level MS obese Non-MS obese Total OR (95% CI) p
High 32 18 50 4,04 (1.62–10.08) 0.002
Normal 11 25 36
Total 43 43 86
Based on genotype CETP −629 C/A gene 
promoter, it was also found that there was no significant 
relationship between AA genotypes in both groups (MS 
obese and non-MS obese) compared to CC genotypes 
against MS risk. A study by Hou et al. found a significant 
differences involving frequency of genotypic distribution 
and alleles from rs1800775 (−629C/A), rs3764261, 
rs12149545, rs711752, and rs708272 between the 
control group and metabolic syndrome (all p < 0.05) [21]. 
The study was conducted in a minority adult population 
in China that included 571 subjects (280 patients and 
291 controls). Our study did not conduct a separate 
analysis of the genotypic distribution of AA, CA, and CC, 
as well as the frequencies of C and A alleles between 
cases and controls [21].
Table 6: Multivariate logistic regression analysis of some risk 
factors MS
Variable OR 95% CI p
CETP high level 2.82 1.07–7.41 0.036
Chemerin high level 2.77 1.04–7.40 0.042
DMT type 2 history in family 2.28 0.63–8.28 0.212
CETP gene polymorphism is consistently 
associated with HDL-C levels, but this does not directly 
affect the level or function of CETP. Research in the 
Caucasian population found that Taq1B polymorphism 
of experienced MS was 4 times in chemerin high level 
subjects compared to normal (OR = 4.04 [95% CI 1.62–
10.08], p = 0.002) (Table 5).
Multivariate analysis with logistic regression 
found that both high levels of CETP and chemerin 
were MS risk factors (OR = 2.82 [95% CI 1.07–7.41], 
p = 0.036; OR = 2.77 [95% CI 1.04–7.40], p = 0.042, 
respectively), while the history of type 2 DM in family 
did not show significant relationship (OR = 2.27 [95% 
CI 0.63–8.28], p = 0.212) (Table 6).
Discussion
The increasing prevalence of obesity in 
childhood and adolescence poses a growing problem. 
Obese children tend not only to become obese adults 
but also obesity is associated with a wide range of 
serious complications already seen in childhood. 
Obese children and adults without cardiovascular risk 
factors have been classified as metabolic healthy obese 
whereas if there were already risk factors classified as 
metabolic unhealthy obese [18].
Table 4: Metabolic syndrome risk based on CETP serum levels
CETP level MS obese Non-MS obese Total OR (95% CI) p
High 31 17 48 3.95 (1.60-9.76) 0.002
Normal 12 26 38
Total 43 43 86
Table 3: Genotype frequency and -629C/A alleles 
polymorphism in MS obese and non-MS obese groups
Genotype SM obese Non-SM obese Total OR (95%CI) p
AA 6 7 13 0.81 (0.23–2.88) 0.75
CA 18 18 36 0.95 (0.38–2.37) 0.91
CC 19 18 37 1.00
Alel
A 30 32 62 0.91 (0.39–2.14) 0.83
C 56 54 110 1.00
Figure 2: Receiver operating characteristic (ROC) curve CETP level (left) and chemerin level (right)
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is complete related to −629C/A, a functional 
polymorphism located in the CETP gene promoter 
region. This promoter polymorphism has been shown 
affects the expression of the CETP gene and this can 
explain the relationship between Taq1B polymorphism, 
plasma CETP, and HDL-C levels [22].
In our study, bivariate analysis showed that 
high levels of CETP were risk factors of MS compared to 
CETP low levels. Multivariate analysis the relationship 
remained significant (OR = 2.82 [95% CI 1.07–7.41], p = 
0.036), despite the relationship rs1800775 polymorphism 
between cases (MS obese) and non-MS obese is not 
significant. A study of Maroufi et al. found that CETP 
levels were significantly higher in the adult MS group 
(1.64 ± 0.32 µg/mL) than healthy controls (1.53 ± 0.34 
µg/mL) [23]. In this study, CETP levels in MS obese 
groups and non-MS obese (2.49 ± 1.03 µg/mL vs. 2.04 ± 
0.92 µg/mL) were higher than the previous studies. The 
previous studies have not been reported cutoff point 
CETP levels. In our study, cutoff point CETP levels were 
as follows: ≥2 µg/mL categorized as CETP high levels 
and <2 µg/mL categorized low levels. CETP is a plasma 
protein that plays a role in the transport of cholesterol 
esters and TG between lipoprotein so that TG of VLDL 
or LDL will have exchange with HDL-C cholesterol ester, 
but the relationship between CETP gene polymorphism 
and CETP levels is complex and ambiguous [24]. 
Human CETP level and its expression are controlled 
by several factors, such as corticosteroids, fatty acids, 
cellular cholesterol levels, and transcription factors [25].
In this study, we obtained chemerin high 
level as a risk factor for MS compared to normal 
chemerin, and in multivariate analysis, this relationship 
remained significant (OR = 2.77 [95% CI 1.04–7.40], 
p = 0.042). Research from Zanganeh et al. in 2016 
found significant differences in serum chemerin levels 
between MS patients and healthy individual controls, 
with a mean age of 42.1 years. Significant differences 
were also obtained for BMI, WC, systolic and diastolic 
blood pressure, IR, and TG (p < 0.001) [26]. In human 
research, chemerin is related to the development of 
obesity and the IR. Circulating chemerin levels increase 
according to the degree of obesity, marked by an 
increase in BMI and WC, suggesting that chemerin is 
related to size and adipocyte differentiation [16]. Recent 
studies have shown a close relationship between 
increased chemerin levels and changes in lipid profiles, 
such as each increase in TG and LDL and decreasing 
HDL-C levels, suggesting that chemerin can contribute 
to increasing atherosclerosis [27]. There are several 
differences in the mean serum chemerin levels of 
various studies and no one has mentioned the cutoff 
point value that divides into high and normal levels. In 
healthy populations, circulating serum and total plasma 
chemerin levels range from 90 to 200 ηg/mL [28]. This 
difference may be due to differences in race or ethnic 
group, study population, differences in measurement 
devices, and protocols by different manufacturers.
There is limitation in this study that only 
examined 1 polymorphism (CETP -629C/A gene 
promoter [rs1800775]). As known, there are more than 
180 SNPs in the CETP gene and 13 polymorphisms in 
the CETP promoter region [21], [29].
Conclusion
Based on the results of the above research, it 
can be concluded that high levels of serum CETP are 
risk factors for MS in obese adolescents and high levels 
of serum chemerin are risk factors for MS in obese 
adolescents. On the CETP −629C/A (rs1800775) gene 
polymorphism, AA genotype is not risk factor for MS, 
and based on allele, A allele carrier is not a risk factor 
for MS in obese adolescents.
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